| Drugname |
Patent Number |
Patent Title |
Patent Assignee |
Estimated Expiration |
| BIIB021 |
➤ Sign Up |
Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
Signal Pharmaceuticals, LLC (San Diego, CA) |
➤ Sign Up |
| BIIB021 |
➤ Sign Up |
2-aminopurine analogs having HSP90-inhibiting activity |
Conforma Therapeutics Corporation (San Diego, CA) |
➤ Sign Up |
| BIIB021 |
➤ Sign Up |
Methods of using MEK inhibitors |
Exelixis, Inc. (South San Francisco, CA) |
➤ Sign Up |
| BIIB021 |
➤ Sign Up |
Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer |
Exelixis, Inc. (South San Francisco, CA) |
➤ Sign Up |
| BIIB021 |
➤ Sign Up |
Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha |
Exelixis, Inc. (South San Francisco, CA) |
➤ Sign Up |
| BIIB021 |
➤ Sign Up |
GRP94 inhibitors |
University of Kansas (Lawrence, KS) |
➤ Sign Up |
| Drugname |
Patent Number |
Patent Title |
Patent Assignee |
Estimated Expiration |
This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
